BPC-157
TL;DR
BPC-157 is a 15-amino-acid pentadecapeptide with broad animal evidence for tissue repair but very limited human efficacy data. The strongest completed human evidence is two small uncontrolled studies — a retrospective knee-pain series (N=12) and an interstitial-cystitis pilot (N=12). One Phase 2 RCT for hamstring strain is recruiting. Human oral PK is unresolved; no validated human dosing standard exists. For Vitals: no BPC-specific detection claim, no oral-confidence claim, context-aware recovery interpretation only.
Why it matters for Vitals
Users may be taking BPC-157 for injury, musculoskeletal recovery, or performance optimization. Vitals relevance:
- What we can do: Coach recovery context when a user has a declared injury and is using BPC-157 alongside rehab. Store peptide use as context for interpreting HRV/sleep/recovery trends.
- What we cannot do: Detect BPC-157 exposure from wearable data alone. Infer success or failure from biometrics without considering confounders (rehab, deload, natural healing, analgesics, illness).
- Detection posture: No-call default. Any detectable signal would be indirect and indistinguishable from general recovery improvement.
Evidence Boundary
| Layer | What exists | What this justifies |
|---|---|---|
| Human efficacy | Retrospective knee-pain series, 12-patient interstitial-cystitis pilot, 2-person IV safety pilot, NCT02637284 (oral, no posted results), NCT07437547 (Phase 2 recruiting) | Saying human signals are small and uncontrolled; Phase 2 results are not yet available |
| Animal efficacy | Broad tendon, muscle, ligament, bone, inflammatory models with favorable structural/functional outcomes | Scientific interest; mechanistic hypothesis quality; NOT human proof |
| Mechanism | VEGFR2-Akt-eNOS, ERK1/2, FAK-paxillin, GHR upregulation, anti-inflammatory signaling | Biological plausibility; NOT clinical efficacy confirmation |
| PK | Rat/dog IV/IM: half-life <30 min; IM bioavailability ~14–51% (species-dependent) | Route realism for animal work; NOT human oral PK |
| Safety | Animal safety summaries + tiny human pilot exposure | Short-term tolerability signal only; NOT long-term safety establishment |
| Wearable | No human wearable-endpoint studies | No BPC-specific detection model; contextual recovery interpretation only |
Human Clinical Evidence
| Study | Design | N | Route | Headline result | Grade |
|---|---|---|---|---|---|
| Lee & Padgett 2021 | Retrospective chart review | 12 BPC-only subgroup | Intra-articular injection for knee pain | 11/12 reported significant improvement | Reported — no comparator |
| Lee et al. 2024 | Uncontrolled pilot | 12 | Procedural/local for interstitial cystitis | 10/12 complete resolution; 2/12 partial | Reported — no control arm |
| Lee & Burgess 2025 | Pilot safety | 2 | IV infusion up to 20 mg | No short-term adverse effects reported | Reported — N=2 tolerability only |
| NCT02637284 (PCO-02) | Phase 1 registry | 42 planned | Oral tablets | No posted results | Gap |
| NCT07437547 | Phase 2 RCT recruiting | 120 planned | Daily SubQ + rehab for grade II hamstring strain | Not yet reported | Gap — trial existence ≠ efficacy |
Bottom line: Human evidence is not zero, but it is structurally weak and too small to support broad repair claims. The 2025 orthopaedic systematic review identified 35 preclinical studies and 1 clinical study in the orthopaedic review window.
Animal Evidence Architecture
Preclinical literature spans multiple repair domains — this breadth explains the sustained scientific interest, but must not be read as human translation:
| Domain | Model classes | Reported outcome pattern |
|---|---|---|
| Tendon | Achilles/quadriceps transection, tendon-bone defects | Better structural organization, biomechanics, limb alignment |
| Muscle | Muscle transection, crush injury, corticosteroid-impaired healing | Improved load-to-failure, less atrophy/gapping |
| Ligament | Rat MCL transection | Less valgus instability / contracture, improved motor function |
| Bone | Rabbit nonunion / fracture-healing | Improved defect resolution, callus/mineralization |
| Inflammatory / systemic | Adjuvant arthritis, GI/cytoprotective models | Anti-inflammatory and cytoprotective signals across tissues |
Mechanism Summary
BPC-157’s pro-repair narrative centers on:
- VEGFR2 → Akt → eNOS / Nitric Oxide — angiogenesis and endothelial signaling; bidirectional NO modulation; supports vasodilation and hypovascular-tissue healing
- ERK1/2 Endothelial Signaling — endothelial proliferation, migration, and vascular tube formation
- FAK-Paxillin / Fibroblast Migration — enhanced cell migration across wound bed
- Growth Hormone Receptor Upregulation — sensitizes tendon fibroblasts to endogenous GH (up to ~7× in vitro/ex vivo)
- Anti-inflammatory Signaling — IL-6, TNF-α, IL-1β, COX-2 suppression
Evidence level: All of the above is preclinical/mechanistic. Human efficacy translation is not established.
Pharmacokinetics
| PK fact | Current best answer | Evidence |
|---|---|---|
| Elimination half-life (IV/IM) | ~15 min (rat); ~5 min (dog); <30 min parent in both species | Animal only |
| IM absolute bioavailability | ~14–19% (rat); ~45–51% (dog) | Animal only |
| Human oral PK | Unresolved — Phase 1 registry entry exists (NCT02637284) but no posted results | Gap |
| Human injectable PK | No directly published human ADME dataset identified | Gap |
Route reality: Consumer oral-absorption claims are not backed by accessible human PK data. Injectable animal PK is real; human injectable PK is not well-characterized.
Safety and Risks
| Topic | Status |
|---|---|
| Short-term human tolerability | Signal exists (N=2–12, uncontrolled); not equivalent to established safety |
| Long-term human safety | Gap — no robust controlled program identified |
| Drug-drug interactions | Gap — no human interaction trials identified |
| Pregnancy / lactation / fertility | Gap |
| Oncology | Theoretical unresolved risk via VEGFR2/angiogenic pathways; pro-repair signaling in undiagnosed malignancy is a legitimate concern; not proven harm, but also not reassuring |
| Regulatory | Not FDA approved; FDA Category 2 bulk drug (compounding restriction since 2023); WADA banned S0 |
| Product quality | Unregulated sourcing creates real-world identity/contamination/sterility risk that exceeds published-study risk |
Phrase rule: “No adverse effects reported” ≠ “established safe.” Only the first is supported.
Regulatory and Sports Status
- FDA: Not approved; Category 2 bulk drug substance (compounding restriction in effect)
- WADA: Banned under S0 (unapproved substances), in and out of competition
- ClinicalTrials.gov: NCT07437547 (Phase 2, recruiting); NCT02637284 (Phase 1 oral, no posted results)
What stays inside this hub
- Formulation/proprietary engineering details
- Specific consumer dosing routines not validated by controlled human trials
- Obscure metabolite fragment names beyond the primary PK paper
- Pipeline/trivia detail about specific companies
Vitals Implementation
Safe vs unsafe language
| Safe now | Do NOT say |
|---|---|
| ”BPC-157 remains investigational in humans." | "BPC-157 is proven to heal injuries in humans." |
| "No validated wearable signature exists." | "We detected BPC-157 from your Apple Watch." |
| "Recovery metrics improving in injury context." | "BPC-157 is definitely working." |
| "Oral exposure remains unresolved." | "Oral BPC-157 bioavailability is established." |
| "User-reported peptide use may be stored as context." | "Readiness should be boosted because the user is on BPC-157.” |
Coaching posture
- Coach the recovery context, not the peptide.
- Do not claim BPC detected or BPC is working.
- If wearables improve, do not attribute specifically to BPC-157.
- If wearables stay flat, do not infer non-response.
- Any observable change would likely manifest as days-to-weeks of recovery-context improvement, not acute peptide detection.
Confounders that override contextual interpretation
- Natural healing trajectory
- Rehab adherence or PT activity changes
- NSAID / analgesic changes
- Alcohol changes
- Acute illness
- Travel / sleep disruption
- Training load changes
- Multiple overlapping recovery agents
Relationship to Existing Mechanism Notes
- Tissue Repair — BPC-157 is the primary angiogenesis driver in this shared mechanism. The Tissue Repair note covers VEGFR2-Akt-eNOS, FAK-paxillin, GHR upregulation, and ECM remodeling as shared biology with TB-500 and GHK-Cu.
- GHK-Cu — cited in stack discussions as a theoretical FAK-paxillin suppressor (cancer risk mitigation angle); mechanistic overlap in angiogenesis and NF-κB suppression.
Related Notes
- Peptides MOC
- Tissue Repair (shared mechanism note)
- GHK-Cu (angiogenesis + ECM overlap; FAK-paxillin counterbalance discussion)
- TB-500 (Wolverine Stack — mechanistic partner; both are research-only, WADA-banned)
Sources
- Vasireddi N et al. 2025. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. PMID 40756949 · PMCID PMC12313605
- He L et al. 2022. Pharmacokinetics, distribution, metabolism, and excretion of BPC-157 in rats and dogs. Front Pharmacol. PMID 36588717 · PMCID PMC9794587
- Lee E, Padgett B. 2021. Intra-Articular Injection of BPC-157 for Multiple Types of Knee Pain. Altern Ther Health Med. PMID 34324435
- Lee E et al. 2024. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. PMID 39325560
- Lee E, Burgess K. 2025. Safety of Intravenous Infusion of BPC-157 in Humans: A Pilot Study. Altern Ther Health Med. PMID 40131143
- Sikiric P et al. 2006. Stable gastric pentadecapeptide BPC-157 in trials for inflammatory bowel disease. Inflammopharmacology. PMID 17186181
- ClinicalTrials.gov NCT02637284 — PCO-02 Phase 1 oral tablet; no posted results
- ClinicalTrials.gov NCT07437547 — BPC-157 for Acute Hamstring Muscle Strain Repair; Phase 2 RCT, recruiting
- McGuire FP et al. 2025. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. PMID 40789979 · PMCID PMC12446177